How Home Health Agencies Are Valued
Home health agencies benefit from one of the strongest secular tailwinds in healthcare: the shift from institutional to home-based care. With 10,000 Americans turning 65 every day and CMS actively incentivizing care-at-home models through programs like PDGM (Patient-Driven Groupings Model), acquirers are paying premium multiples for well-run home health operations.
Single-Branch Agencies (Under $5M Revenue)
A single-branch home health agency typically sells for 3-6x EBITDA or 0.8-1.2x revenue. An agency with $3M in revenue and $450K EBITDA would sell for $1.35M to $2.7M. At this size, buyers include regional operators, hospital systems looking to vertically integrate, and PE add-on platforms filling coverage gaps.
Regional Multi-Branch Agencies ($5M-$25M Revenue)
Multi-branch agencies operating across a metro area or state command 6-9x EBITDA. The premium reflects geographic density, referral network breadth, and operational infrastructure (compliance, billing, quality assurance) that scales across branches. A 4-branch agency generating $15M revenue and $2.25M EBITDA could sell for $13.5M to $20.25M.
Multi-State Platforms ($25M+ Revenue)
Platform-quality home health businesses with multi-state licenses, established compliance infrastructure, and $3M+ EBITDA command 9-12x EBITDA. Buyers at this level include large PE-backed platforms like Amedisys, LHC Group (now part of UnitedHealth/Optum), and BrightSpring Health Services. These deals often include earnout provisions tied to census growth.
Key Value Drivers
CMS Star Ratings are the single most scrutinized metric. Agencies with 4+ stars on Home Health Compare have a demonstrable quality advantage that translates to referral preference, better ACO partnerships, and potential value-based purchasing bonuses. A drop from 4 to 3 stars can reduce your multiple by 1-2x.
Medicare vs. Medicaid mix directly drives margins. Medicare home health reimburses significantly higher than Medicaid. Agencies with 60%+ Medicare census generate stronger EBITDA margins (15-20%) versus Medicaid-heavy agencies (8-12%). Buyers price this difference directly.
Referral source diversification is critical. An agency where one hospital system accounts for 50%+ of admissions faces concentration risk. The strongest agencies have 30+ active referral relationships across hospitals, physician groups, skilled nursing facilities, and ACOs.
Nurse and aide retentionremains the industry's existential challenge. Agencies with turnover rates below 40% (the industry average is 60%+) command premium valuations because workforce stability directly drives census capacity and quality scores.
Regulatory Considerations
Home health is heavily regulated. Buyers conduct extensive diligence on Medicare certification and survey history, state licensing, OASIS documentation accuracy, and billing compliance. Any history of ADRs (Additional Documentation Requests), RAPs under review, or state survey deficiencies will reduce your valuation or kill a deal entirely.